|
|
|
|
|
|
|
|
Full text
Conclusion
In summary, KRAS mutation is a common event in ovarian cancer and is more frequently present in carcinoma
of lower grade, lower FIGO stage, and in lesions of mucinous histotype. Our results
support earlier findings from other groups in a very large number of samples. KRAS mutation was not found to be of prognostic value for patients under standard therapy,
but these mutations could emerge as an important factor for individually tailored
anti-EGFR therapies.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.